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Impaired synaptic integrity and function due to accumulation of amyloid β-protein (Aβ42)
oligomers is thought to be a major contributor to cognitive decline in Alzheimer’s
disease (AD). However, the exact role of Aβ42 oligomers in synaptotoxicity and
the ability of peripheral innate immune cells to rescue synapses remain poorly
understood due to the metastable nature of oligomers. Here, we utilized photo-induced
cross-linking to stabilize pure oligomers and study their effects vs. fibrils on synapses
and protection by Aβ-phagocytic macrophages. We found that cortical neurons
were more susceptible to Aβ42 oligomers than fibrils, triggering additional neuritic
arborization retraction, functional alterations (hyperactivity and spike waveform), and
loss of VGluT1- and PSD95-excitatory synapses. Co-culturing neurons with bone
marrow-derived macrophages protected synapses against Aβ42 fibrils; moreover,
immune activation with glatiramer acetate (GA) conferred further protection against
oligomers. Mechanisms involved increased Aβ42 removal by macrophages, amplified
by GA stimulation: fibrils were largely cleared through intracellular CD36/EEA1+-early
endosomal proteolysis, while oligomers were primarily removed via extracellular/MMP-9
enzymatic degradation. In vivo studies in GA-immunized or CD115+-monocyte-grafted
APPSWE/PS11E9-transgenic mice followed by pre- and postsynaptic analyses of
entorhinal cortex and hippocampal substructures corroborated our in vitro findings
of macrophage-mediated synaptic preservation. Together, our data demonstrate that
activated macrophages effectively clear Aβ42 oligomers and rescue VGluT1/PSD95
synapses, providing rationale for harnessing macrophages to treat AD.
Keywords: Alzheimer’s disease, neurodegeneration, immunomodulation therapy, amyloid-beta, regeneration,
synaptogenesis
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive, incurable and fatal
neurodegenerative disorder and the most frequent cause of
senile dementia (1, 2). AD is characterized by severe synaptic
and neuronal loss resulting in gradual behavioral and cognitive
decline (3, 4). Early pathological changes in AD involve
accumulation of amyloid β-protein (Aβ) in the brain and retina
(5–11), with the amyloidogenic 42-residue long alloform (Aβ42)
viewed as the most pathognomonic (5, 12). These Aβ42 peptides
have been shown to rapidly aggregate into insoluble fibrils
that form the plaques in AD brains, but also to assemble
into non-fibrillar soluble oligomers, believed to be highly
neurotoxic (8, 13–20). While there is a weak correlation between
cerebral plaque density and severity of AD, Aβ42 oligomers
appear to closely associate with synaptopathy and cognitive
impairment (21, 22). Specifically, growing evidence demonstrates
the detrimental effects of Aβ42 oligomers on synaptic plasticity,
spine morphology and density (13, 23), axonal transport (24–26),
and cognition (8, 15, 17, 22, 27–29). These findings incentivize
strategies that eradicate Aβ42 oligomers in order to preserve
synapses and cognitive function (30–34).
Multiple mechanisms mediate cerebral Aβ clearance,
including phagocytosis and enzymatic degradation by innate
immune cells such as microglia and bone marrow (BM)-derived
monocytes (Mo) and macrophages (M8) (35, 36). However,
under a chronic neuroinflammatory condition typical for AD,
microglia exhibit a compromised phenotype, with diminished
ability to clear Aβ (37, 38), further contributing to damaging
inflammatory processes, and excessively pruning synapses (39–
46). Nevertheless, unlike brain-resident microglia, BM-derived
Mo/M8 appear to have an increased capacity to remove Aβ
fibrils, as shown by studies in both cell cultures and animal
models (47–64). Indeed, various pre-clinical studies from our
group and others have supported an emerging paradigm shift for
the therapeutic potential of immunomodulation via enhanced
cerebral recruitment of BM-derived Aβ-clearing macrophages
(9, 35, 50, 52, 58, 62–70). In particular, we demonstrated
that successful delivery of therapeutic Mo/M8 to the brains
of APPSWE/PS1dE9 double-transgenic (ADtg) mice can be
achieved via immunization with altered myelin-derived antigens
(e.g., glatiramer acetate – GA; also known as Copaxone R©)
or peripheral-blood enrichment with BM-derived CD115+-
monocytes (MoBM) (50, 52, 58, 63, 70). In the immunized mice,
cerebral M8 were found to be highly-phagocytic, pro-healing,
and anti-inflammatory, profoundly alleviating cerebral Aβ40
and Aβ42 burden, reducing microgliosis and astrocytosis, and
ultimately improving cognitive functions. Further, GA induced
macrophage-mediated recognition and phagocytosis of fibrillar
Aβ42 (63, 70). However, the potential of clearing the non-
fibrillar, soluble Aβ42 oligomeric forms by macrophages requires
further investigation.
Experimental and clinical studies have indicated that the
cognitive decline seen in AD patients and animal models is
related to early pathological processes occurring in entorhinal
cortex layers 2 and 3 (71–75). These layers play a crucial
role in connecting brain cortical regions to the hippocampus.
Our immunomodulation approach of recruiting Mo/M8 to
brain sites of Aβ deposits substantially reduced AD-related
pathology within these regions (63, 70). Importantly, selective
ablation of peripheral monocytes, either by diphtheria toxin-
targeted depletion or Ccr2-mediated inhibition of cerebral
monocyte infiltration, exacerbated cortical and hippocampal Aβ
pathology in ADtg mice (52, 53). In addition, our preliminary
data suggested a presynaptic preservation concomitant with
Aβ-plaque reduction in hippocampi of these murine models
(63). Yet, the underinvestigate role of peripheral Mo/M8
in preservation of synaptic and neurite integrity, especially
postsynaptic terminals within AD-relevant cortical regions, calls
for broader exploration due to promising clinical implications of
immunomodulation intervention strategies for AD.
Here, we applied photo-induced cross-linking of unmodified
proteins (PICUP) to assess the impact of intrinsically metastable
and polydisperse Aβ42 oligomers on neurons and to test the
ability of macrophages to recognize, bind to, and remove them
(76, 77). This technique allowed us to produce pure, stabilized
assemblies of low-n Aβ42 oligomers (XL-oAβ42). The precise
detrimental impact of these oligomeric conformers, as compared
with preformed fibrils (fAβ42), was determined on synaptic
density, neuritic arborization length, and neuronal function
in primary (P1) cortical neurons. Furthermore, synaptic and
neurite protection against Aβ42 oligomers was explored in co-
cultures of cortical neurons accompanied with BM-derived M8
or GA-activated M8. Next, the innate immune mechanisms
of eliminating pathogenic Aβ42 assemblies and subsequently
attaining synaptic rescue were studied. Finally, in ADtg mice,
we determined synaptic loss as well as preservation of pre-
and postsynaptic terminals following macrophage-mediated
immunomodulation interventions in predefined hippocampal
and cortical subregions.
MATERIALS AND METHODS
Mice
Alzheimer’s disease double-transgenic (ADtg) B6.Cg-Tg
(APPswe, PSEN11E9) 85Dbo/J mice and their age-matched
wildtype (WT) C57BL/6J littermates were purchased from
Jackson Laboratories (MMRRC stock 34832-JAX) and then bred
and maintained at Cedars-Sinai Medical Center. All animals in
this study have a C57BL/6 congenic background. Two cohorts
of 10-month-old males, WT and ADtg (n = 6 per experimental
group), were used. The first cohort underwent weekly s.c. GA
immunization or monthly i.v. CD115+-MoBM injections for a
duration of 2 months. Control groups were comprised of either
naïve WT mice or monthly i.v. PBS injected ADtg mice. At the
completion of the experiment, mice underwent behavioral testing
at 12 months of age, then were perfused, under deep anesthesia,
with ice-cold 0.9% saline solution containing 0.5mM EDTA, and
brains were collected for analyses. Harvested brains were cut in
half. One hemisphere was post-fixed overnight in phosphate-
buffered saline (PBS) containing 2.5% paraformaldehyde. Tissue
was cryoprotected and stored in PBS containing 30% sucrose
and 0.1% sodium azide. Brains were cut coronally in 30µm
serial sections for histology. The second hemisphere was further
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snap-frozen for biochemical and molecular assays as described
previously (63). The second cohort underwent perfusion as
described above for tissue collection.
Culture and Co-culture of Primary Cortical
Neurons and Macrophages
Cortical neuronal cultures were prepared from postnatal day
1 C57BL/6 mice (78, 79). Neonates were decapitated, and
their brains were removed. The cerebral cortex was dissected,
stripped of meninges, dissociated with a combination of calcium
and magnesium free Hank’s balanced salt solution (HBSS;
Life Technologies) containing 0.2% w/v papain suspension
(Worthington Biochemical), and digested for 12min at 37
◦
C.
The triturated cells were passed through a 70µm strainer
and counted. The cells were plated in laminin and poly-D-
lysine-coated coverslips (BD Biosciences) at a density of 8 ×
104 cells per ml (in 24-well plates) in NbActiv4 (BrainBits),
then supplemented with 100 units/ml penicillin and 100µg/ml
streptomycin. The purity of primary neurons was about 92–94%
(78). Bone marrow-derived macrophages were obtained as
described previously (63). Briefly, bone marrow cells were
isolated from the femurs and tibiae of 8- to 16-week-old
C57BL/6 mice, differentiated into macrophages by incubation
in complete RPMI-1640 (Life Technologies), and supplemented
with 10% fetal bovine serum (Life Technologies) and 20 ng/ml
macrophage colony stimulating factor (M-CSF; PeproTech) for
5 days. Primary cultures of macrophages were then suspended
in NbActiv4 and co-cultured with primary cortical neurons
(ratio of 1:1) per well in 24-well tissue-culture plates for 2
days. Primary neurons and/or macrophages were incubated
overnight with 100nMof scrambled (s), fibrillar (f), or oligomeric
(o) Aβ42 (see below “Preparation of Aβ1−42 oligomers, fibrils
and Scrambled Aβ42”). Additional groups included those with
macrophages treated with glatiramer acetate (GA; 30µg/ml,
TEVA Neuroscience) for 24 h. Experiments were carried out at
day 9 of seeding cortical neurons starting with synapse formation
andmaturation (78). Cultures were washed in PBS and then fixed
in 4% formaldehyde for 20min at room temperature for further
experimental procedures.
Microelectrode Array Recording
Cortical neuronal cultures (as described above) were plated
in a M768-GLx 12-, 24-, or 48-well plate (Axion Biosystems).
Preformed Aβ42 (100 nM) were added to the culture on day 9.
Simultaneous recordings from 64 extracellular electrodes per well
weremade using theMaestro (Axion BioSystems)microelectrode
array (MEA) system at a constant temperature of 37◦C. Data
were sampled at 12.5 kHz, digitized and analyzed using Axion
Integrated Studio software (Axion BioSystems) where spike
events were detected using an adaptive spike detection threshold
of 5.5 SD for each electrode with 1 s binning. Detected waveforms
were then further sorted usingOffline Sorter v4 software (Plexon)
and exported through NeuroExplorer (Nex Technologies) into
MatLab for waveform analysis using custom code. All data is
presented as means ± s.e.m. and include recordings from 5
independent experiments.
Amyloid-β42 Determination by Sandwich
ELISA
At day 7, macrophages were incubated for 30min or 24 h with
fibrillar (f) or oligomeric (o) Aβ42 and thereafter culture medium
was collected. Total protein levels in the supernatant were
determined using the Pierce BCA Protein Assay Kit (#23227;
Thermo Scientific). The Aβ42 levels in the supernatant were
assessed using a sandwich ELISA for an anti-human Aβ42 end-
specific kit (KHB3442, Invitrogen; which does not recognize
mouse Aβ nor human Aβ40/Aβ43). The kit was used according
to the manufacturer’s instructions. This assay is based on a
combination of two antibodies specific for the N- and the
COOH-termini of Aβ42 sequences. The bound rabbit anti-
COOH-terminus was detected with a horseradish peroxidase-
labeled anti-rabbit antibody and was read at 450 nm using a
microplate reader (Spectra Max 384 plus, Molecular Devices).
Concentrations detected at 24 h incubation were normalized to
basal levels at 30 min incubation.
Immunocytohistochemistry and
Quantification of Synapses and Neurites
Primary neurons/macrophages in coverslips and brain coronal
cryosections at bregma −2.50, −2.65, and −2.80mm (80)
per animal were washed in PBS and then treated with
a permeabilization/blocking solution containing 20% normal
horse serum (Invitrogen) and 0.05% Triton X-100 (Sigma-
Aldrich). Cells or tissue sections were stained overnight at 4◦C
with combinations of presynaptic marker VGluT1 (Chemicon,
1:6,000), postsynaptic marker PSD95 (Abcam, 1:600; for
synapses), or neuron-specific class III beta-tubulin/Tuj1 (Abcam)
or Tubb3 (BioLegend; for neurites; Supplementary Table 1)
in 2% blocking solution in PBS. Secondary antibodies of
Cy3 donkey anti-guinea pig or anti-mouse or Cy5 donkey
anti-rabbit (Supplementary Table 1) were incubated for 1 h at
room temperature. The samples were washed in PBS and
mounted using ProLong R© Gold with DAPI (Life Technologies).
All groups were immunostained using identical procedures.
Negative controls were processed using the same protocol with
the omission of the primary or secondary antibodies to assess
nonspecific labeling. There was no specific staining with these
negative controls. Microphotographs were shot using a Carl
Zeiss Axio Imager Z1 fluorescence microscope equipped with
ApoTome (AxioVision 4.6.3, Carl Zeiss). The parameters for
scanning were consistent across all groups.
Synaptic and neuritic quantification of primary cultures
in vitro was carried out from 16 images, each coverslipped
at a 40× objective lens. At least 2 coverslips, 32 images, and
150 neurons for each condition were analyzed. For synaptic
analysis in vivo and to cover the hippocampal area, 3 of
the same rectangular fields (90 × 70µm) under 100× oil
objective lens were precisely selected in the lateral and medial
blade molecular layer (ML) of the dentate gyrus (DG), the
stratum lacunosum-moleculare (SLM), the stratum radium (SR)
and the stratum oriens (SO) of cornu ammonis 1 (CA1) in
each condition, respectively. In addition, 2 of the same fields
were carefully chosen in layers 2 and 3 of the entorhinal
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cortex (ENT). Fifteen optical sections per field, 15 fields per
hippocampal area, 4 fields per entorhinal cortex per section, and
855 total images per brain were analyzed. Single optical section
images at 0.25µm intervals and 3.75µm Zeiss ApoTome high-
resolution scans were performed. Synaptic puncta number and
synaptic immunoreactive (IR) area were quantified using Puncta
Analyzer (81, 82) and ImageJ (NIH) macro and batch process.
Total neurite length was measured using the NeuriteTracer
program (83). Briefly, the cultures were immunostained with
Tuj1 for neurite and NeuN for the neuronal nucleus. For each
condition, at least 150 primary neurons, 32 images in random
fields from 2 coverslips in 2 independent experiments were
analyzed. The NeuriteTracer was utilized to detect the neurites
strongly stained for Tuj1. Following optimization of parameters
to separate neurites from the neuronal cell body and tracing
the neurite through skeletonization, positively labeled neurites
and respective lengths were quantified (Figure 3B). The observer
was blind to the treatment conditions. Average puncta number,
synaptic area, and percentage of the area per image or per neuron
were calculated for each condition.
Primary Cultures of Bone Marrow-Derived
Macrophages and the Phagocytosis Assay
To test amyloid-β phagocytosis by macrophages, in repeated
experiments monocytes were isolated from the bone marrow
of wild-type mice (n = 18 mice) and differentiated into
macrophages by 7-day cultivation in complete RPMI-1640
medium (#21870; Life Technologies) with 10% serum and
20 ng/ml MCSF (#315-02; PeproTech). Macrophage primary
cultures were then plated at 1.2× 105 cells per well (3–4 wells for
each condition) in 24-well tissue-culture plates on glass coverslips
overnight. Next, macrophages were either treated with 30µg/ml
GA (Copaxone R©; TEVA Neuroscience) for the duration of 1,
3, or 24 h, or not treated (control group). Before addition of
f/o/sAβ42 or vehicle, the cells were chilled in a 4
◦C ice bath
for 5min; immediately after addition of the preformed Aβ42
(100 nM), the plates were centrifuged at 515g in 25◦C followed
by incubation at 37◦C for 30 or 60min. The cells were then
rinsed with Aβ-free medium to remove non-incorporated Aβ
and later washed twice with PBS. Methanol (99.8%) at −20◦C
for 20min or 4% paraformaldehyde at room temperature for
12min were used for fixation of the cells followed by repeated
washes with PBS. For immunostaining, the cells were first stained
using the mouse anti-human amyloid-β mAb clone 6E10 (1:100;
SIG-39320; Covance), rat anti-CD36 mAb clone MF3 (1:200;
ab80080; Abcam), rat anti-CD204 scavenger receptor type I/II
(SCARA1) mAb (1:100; MCA1322; AbD Serotec), rabbit anti-
EEA1 pAb (1:100; Millipore #07-1820) and goat anti-MMP-
9 pAb (1:100; AF909; R&D systems; Supplementary Table 1).
Secondary polyclonal antibodies included donkey anti-mouse,
anti-rat, anti-rabbit, and anti-goat conjugated with Cy2, Cy3, or
Cy5 (1:200; Jackson ImmunoResearch Laboratories). The cells
were mounted using ProLong R© Gold with DAPI (Molecular
Probes, Life Technologies; Supplementary Table 1). Several
fields (minimum n = 5 randomly selected per group) were
obtained from each well using a Carl Zeiss Axio Imager Z1
ApoTome-equipped microscope (an average of 120 cells in
each field). Images were obtained using the same exposure
time on each occasion. The fluorescent signal and its total
area were determined and quantified by the conversion of
individual images to greyscale and standardizing to baseline
using histogram-based thresholds with NIH ImageJ software.
The “mean area per cell” was a result of a numerical average
of the individual cell’s immunoreactive area per field. The
“area/cell” measures the total fluorescent signal (area) divided
by the total number of cells (DAPI count) of the same field
(image). For all experiments, the investigators were blinded to
the treatment condition. Colocalization of EEA1-6E10 (puncta
analysis) was performed as synaptic puncta number analysis
described above (81, 82).
Preparation of Aβ1−42 Oligomers, Fibrils,
and Scrambled Aβ42
Filtration was used to prepare LMW Aβ42 as described (84).
Microcon YM-30 filters (EMD Millipore) were washed in 200µl
of distilled deionized water. Aβ was dissolved in 10% (v/v)
60mM NaOH and 90% (v/v) 10mM phosphate buffer, pH
7.4, at a concentration of 1mg/ml. The solution was sonicated
for 1min and then placed into the washed filter. Following
centrifugation at 14,000 × g for 20min, the filtrate, LMW
Aβ42, was collected. This LMW Aβ was stabilized using photo-
induced cross-linking of unmodified proteins (PICUP) (76,
85–87) to yield a distribution of “oligomeric Aβ.” Briefly,
2mM Tris(2,2′-bipyridyl)di- chlororuthenium(II) hexahydrate
(Ru(Bpy); Aldrich) and 40mM ammonium persulfate (APS;
Sigma) were prepared in distilled deionized water. An 18µl
aliquot of 80µM LMW Aβ42 was placed in a PCR tube,
followed by 1µl of Ru(Bpy) and 1 µl of APS. The sample was
irradiated (150W incandescent lamp) for 1 s and the reaction
was quenched immediately with 1Mdithiothrietol. Cross-linking
reagents were removed by dialysis using 3.5 kDa MWCO Slide-
A-Lyzer cassettes (Pierce) against 10mM sodium phosphate pH
7.4. More than 5 changes of buffer were completed, and protein
purity and concentration were confirmed with optical absorption
spectroscopy and SDS-PAGE.
For preparation of fibrillar Aβ42, LMW Aβ42 was
prepared as described above, and the peptide preparation
was incubated at 100µM with orbital shaking at 37◦C
until fibril formation occurred, approximately 2 weeks. The
presence of fibrils was confirmed by electron microscopy.
We used a previously designed “scrambled” Aβ42 peptide
that: (1) had an amino acid composition identical to that
of wild type Aβ42, and (2) did not display amphipathicity
(as does the wild type peptide). We accomplished this by
using word scrambler software (for example: https://www.
wordunscrambler.net/word-scrambler.aspx) to randomly
permute the Aβ amino acid sequence. We then used Kyte-
Doolittle analysis (88) to determine the hydropathy profiles
of the permuted sequences. This sequence met the 2 criteria
for scrambled Aβ42: YHAGVDKEVVFDEGAGAEHGLAQK -
IVRGFGVSDVSMIHINLF.
Both WT and scrambled Aβ42 were synthesized using
9-fluorenylmethoxycarbonyl (Fmoc) chemistry, purified by
reverse phase-high performance liquid chromatography, and
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characterized by mass spectrometry and amino acid analysis,
as described previously (89). Quantitative amino acid analysis
and mass spectrometry yielded the expected compositions and
molecular weights for each peptide. Purified peptides were
stored as lyophilizates at −20◦C. During fibril assembly studies,
scrambled Aβ42 has been shown to maintain a statistical coil
secondary structure, bind thioflavin T poorly, and exhibit
oligomerization characteristics distinct from those of wild type
Aβ42 (90). Scrambled Aβ42 was dissolved in 10% (v/v) 60mM
NaOH and 90% (v/v) 10mM phosphate buffer, pH 7.4, at a
concentration of 1 mg/ml.
Transmission Electron Microscopy
Ten microliters of Aβwere spotted onto 400 mesh carbon-coated
Formvar grids (Electron Microscopy Sciences) and incubated for
2min. Each grid was then negatively stainedwith 1% (v/v) filtered
(0.2µm) uranyl acetate (Ted Pella), which was immediately
wicked off. Electron microcopy analysis was performed using
JEOL 1200 EX at 80KV (91).
All other experimental protocols, including genotyping, GA
immunization, isolation and adoptive transfer of bone-marrow
CD115+ monocytes, quantification and stereological counting,
and Barnes maze behavioral tests were previously described (63).
Statistics
GraphPad Prism 5.0b (GraphPad Software) was used to analyze
the data. A comparison of three or more groups was performed
using two-way or one-way ANOVA followed by the Tukey’s or
Bonferonni’s (92) post hoc multiple comparison test for paired
groups. Two-group comparisons were analyzed using two-tailed
paired t-tests (StatPlus). Correlation analyses were performed
using the Pearson’s coefficient (r) tests (Prism). Results are
expressed as mean ± standard error of the mean (s.e.m.). A p
value less than 0.05 was considered significant.
RESULTS
Excitatory Synapses Are More Vulnerable
to Aβ42 Oligomers Than Fibrils
To assess the effect of Aβ42 oligomers vs. fibrils on synaptic
integrity and neuronal structure, postnatal day 1 (P1) primary
cortical neurons (CN) were incubated for 12 h with 100 nM of
either defined and stabilized oligomers (XL-oAβ42), preformed
fibrils (fAβ42), or non-aggregated scrambled Aβ control peptides
(sAβ42)(90), compared to medium alone without Aβ (vehicle;
Figures 1A–D). The pure populations of Aβ42 fibrils and
stabilized low-n oligomers were verified by SDS-PAGE gel
and transmission electron microscopy (Figures 1A–C). We
observed no statistical difference in synaptic puncta number
[analyzed by colocalized presynaptic VGluT1 (vesicular
glutamate transporter 1) and PSD95 (postsynaptic density
protein 95)] or neurite length between vehicle and sAβ42 groups
(Supplementary Figures 1A,B). There was also no significant
difference between CN co-cultured for 24 h with BM-derived
M8 for 24 h supplemented with either medium alone or sAβ42
(Supplementary Figures 1A,B). Interestingly, there was a small
but significant increase in VGluT1/PSD95 synaptic number in
cortical neurons following 24 h co-culture with GA-treated M8
(Supplementary Figure 1A). While sAβ42 did not induce loss
of synapses or neuritic length retraction in CN, incubation with
fAβ42, and moreover, with XL-oAβ42 (Figure 1D), decreased
presynaptic VGluT1+ number by 63 and 81%, respectively,
as compared to vehicle (Figure 1E; P < 0.001). Similarly, but
to a lesser extent, postsynaptic PSD95+ puncta numbers were
significantly reduced by 48 and 62% after exposure to fAβ42
or XL-oAβ42, respectively (Figure 1E; P < 0.001). Analysis of
co-localized VGluT1 and PSD95 puncta number indicated a
50 and 70% reduction in synaptic density after 12 h exposure
to fAβ42 or XL-oAβ42, respectively (Figure 1F; P < 0.001).
Importantly, cortical excitatory synapses were substantially
more vulnerable to low-n Aβ42 oligomers than to their fibril
counterparts (Figure 1F; P < 0.001).
Spontaneous Neuronal Hyperactivity and
Altered Spike Waveforms Induced by Aβ42
Oligomers
To examine the functional consequences of exposing neurons
to Aβ42 oligomers vs. fibrils, we recorded the spontaneous
extracellular activity of P1 cortical neurons using Microelectrode
arrays (MEA) after incubation with vehicle, fAβ42, or XL-
oAβ42 for either 24 or 48 h (Figures 2A–G and Supplementary
Figures 2A–D). We first compared the spontaneous activity
levels across all neurons with a level of activity of at least 0.2Hz.
We found that after incubation with Aβ42 oligomers for 24 h,
spontaneous activity levels were significantly larger compared
to incubation with vehicle or fibrils (Figure 2A; P < 0.05),
whereas activity levels for incubation with fibrils was not
significantly different from incubation with vehicle (Figure 2A;
P < 0.05). After 48 h, neurons incubated with either fAβ42
or XL-oAβ42 had significantly elevated levels of spontaneous
activity compared to vehicle (Figure 2B; P < 0.001–0.05). This
shows that incubation with Aβ42 oligomers is accompanied
by hyperactivity as early as 24 h. This was also true when
examining all neurons regardless of spontaneous activity levels
and when only included neurons recorded at both time points
(see Supplementary Figures 2A–C).
Did the presence of oligomers change the biophysical
properties of neurons? To address this question, we next
assessed whether the extracellular waveforms of the recorded
action potentials differed between neurons exposed to fibrillar
and oligomeric forms (Figures 2D–G and Supplementary
Figure 2D). We found that two critical features of the
extracellular waveform changed after incubation with oligomeric
Aβ42. First, the trough-to-peak width of waveforms (Figure 2D)
recorded from neurons incubated with oligomeric Aβ42
was significantly decreased relative to controls after 48 h
(Figure 2E; P < 0.01); this effect was not apparent after
24 h (Supplementary Figure 1D). Second, the repolarization
slope significantly decreased for neurons incubated with
Aβ42 oligomers, but not fibrils, relative to controls after 24 h
(Figure 2F; P = 0.0103), an effect which persisted through 48 h
(Figure 2G; P < 0.05). Together, this shows that incubation
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FIGURE 1 | Impact of defined and stabilized Aβ42 oligomers vs. purified fibrils on synaptic integrity in primary cortical neurons. (A) SDS-PAGE image of cross-linked
(XL+) and non-XL (XL−) Aβ42 oligomers. (B) Electron microscopy (EM) of preformed fibrillar (f)Aβ42 and (C) XL-oAβ42, consisting of a defined distribution of covalently
linked oligomers that were characterized by negative EM stain. Spherical (arrows) and amorphous structures were observed for XL-oAβ42, whereas typical amyloid
(Continued)
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FIGURE 1 | fibrils were seen in fAβ42. (D) Representative high-resolution images of pre-VGluT1 and post-PSD95 synapses in primary cortical neurons, treated with no
(–)Aβ42 (vehicle), fAβ42 or XL-oAβ42. Areas within dashed boxes are magnified below. (E,F) Quantification of pre- and postsynapses in postnatal day 1 (P1) mouse
primary cortical neurons. (E) VGluT1- and PSD95-immunoreactive area per neuron and (F) colocalized VGluT1/PSD95 synaptic puncta number in P1 cortical neurons
treated with vehicle, fAβ42 or XL-oAβ42. ***P < 0.001, fAβ42 vs. vehicle or XL-oAβ42 vs. vehicle; **P < 0.01, fAβ42 vs. XL-oAβ42, by one-way ANOVA and Tukey’s
post-test. Data expressed as mean ± s.e.m.; n = 32 fields analyzed from 2 independent experiments; Scale bars = 100 nm (B,C) and 5µm (D).
FIGURE 2 | Oligomeric Aβ42 assemblies cause neuronal hyperactivity and altered extracellular spike waveforms. Microelectrode array recordings of spontaneous
activity in P1 primary cortical neurons measured 24 and 48 h after addition of vehicle, 100 nM of fAβ42, or of XL-oAβ42. (A,B) Mean neuronal frequency of active
neurons showing spontaneous activity during 5min recordings. Neurons analyzed met a minimum threshold of 0.2Hz firing rate. 24 h, *P < 0.05, vs. Vehicle or fAβ42;
48 h, *P < 0.05, ***P < 0.001, vs. Vehicle; Kruskal-Wallis analysis by Dunn’s test. (C) Comparison of spontaneous activity measured from the same individual neuron
populations over time, from untreated (time 0) to 24 h incubation with vehicle, fAβ42, or XL-oAβ42. ****P < 0.0001, vs. time 0; Kruskal-Wallis analysis by Dunn’s test.
(D) Representative extracellular waveforms from each condition (gray = overlays of multiple waveforms from a single neuron; black = fitted mean waveform for
analysis), identifying the trough-to-peak width (blue) and repolarization slope (orange). Shaded blue box indicates trough-to-peak width observed in control wave
forms, dotted blue lines indicate measurement in XL-oAβ42. Orange hashed lines indicate mean repolarization slope of each wave form. (E) Quantification of
trough-to-peak width in P1 cortical neurons incubated with fAβ42 or XL-oAβ42 for 48 h. **P < 0.01 vs. Vehicle 48 h. (F–G) Quantification of repolarization slope in P1
neurons in each condition. *P < 0.05 vs. Vehicle 24 and 48 h or fAβ42 24 h, respectively. one-way ANOVA and Tukey’s post-test. Data expressed as mean ± s.e.m.,
with individual data point from 5 independent experiments.
with Aβ42 oligomers was accompanied by spontaneous neuronal
hyperactivity and altered extracellular waveforms.
Activated Macrophages Effectively Prevent
Synaptic Loss and Neuritic Arborization
Retraction Caused by Aβ42 Oligomers
To determine whether naïve BM-derived (M8BM) or GA-
activatedmacrophages (GA-M8) can confer neuroprotection, P1
CN were co-cultured with M8BM or GA-M8 in the presence of
fAβ42 or XL-oAβ42 (Figure 3; experimental scheme and neurite
tracing quantification method are shown in Figures 3A,B).
Substantial synaptic loss and neuritic retraction were observed,
especially after exposure to Aβ42 oligomers (Figures 3C,D,F,G vs.
Figure 3E; P < 0.01; 32 and 65% VGluT1/PSD95-synaptic loss
in response to fibrils and oligomers, respectively). Importantly,
reductions in pre- and postsynaptic puncta number (and area)
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FIGURE 3 | Activated M8 effectively protect against oligomeric Aβ42-induced synaptic and neuritic arborization loss in primary cortical neurons. (A) Schematic of the
in vitro experiments (timeline in days). P1 cortical neurons (treated with 100 nM XL-oAβ42, fAβ42, or vehicle for 12 h, respectively), bone marrow-derived M8 (M8
BM),
(Continued)
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FIGURE 3 | and GA-activated M8BM (GA-M8) were cultured for 9 d. (B) Representative microphotographs of P1 neurons labeled with anti-Tuj1 and -NeuN serum
(left), neuritic tracings with NeuriteTracer (83) (middle), and RGB merge tracings (right). Scale bar represents 20µm. (C) Quantification of colocalized VGluT1/PSD95
synaptic puncta number in P1 neurons incubated with fAβ42, XL-oAβ42, or vehicle, and P1 neurons co-cultured with M8 or with GA-M8. Note that fAβ42 and
XL-oAβ42 both reduced the VGluT1/PSD95 synaptic density that was significantly preserved by co-culturing with M8. This effect was enhanced by co-culturing with
GA-M8. (D) Quantification of neuritic length of P1 neurons incubated with fAβ42, XL-oAβ42, or vehicle, and P1 neurons co-cultured with M8 or with GA-M8. Note that
co-culturing with GA-M8 significantly prevented decreases in neuritic length from fAβ42 or XL-oAβ42. Data expressed as mean ± s.e.m.; n = 48 fields analyzed from 3
independent experiments; *P < 0.05, **P < 0.01, comparisons as indicated by lines; #P < 0.05, vs. fAβ42 or XL-oAβ42 alone (no M8), by one-way ANOVA and
Tukey’s post-test. (E-H) Representative microphotographs of primary P1 neurons incubated with (E) vehicle, (F) XL-oAβ42, (G) fAβ42, and (H) co-cultured with GA-M8
+ XL-oAβ42. Scale bar = 20µm.
after exposure to fAβ42 were fully restored when co-cultured with
M8BM or GA-M8 (Figure 3C and Supplementary Figures 3A,
B; P < 0.01), suggesting that M8 have the capacity to effectively
protect synapses against Aβ42 fibril toxicity within this time
frame. However, untreated M8 had limited ability to protect
synapses against damage induced by Aβ42 oligomers (Figure 3C;
P< 0.05), although importantly, GA activation of M8 promoted
full protection also against these highly synaptotoxic oligomers
(Figure 3C and Supplementary Figures 3A,B; P < 0.01). While
minimal to no protection against neuritic arborization loss was
observed following co-culturing cortical neurons with naïve
M8 in the presence of either fAβ42 or XL-oAβ42 (Figure 3D),
significant protection to neuronal dendritic structure was
obtained with GA-activated M8, as measured by neurite process
lengths (Figure 3D; P < 0.05). Interestingly, even in the absence
of Aβ, co-cultures of cortical neurons with GA-M8 vs. naïve
M8 had a significant increase in synaptic density (Figure 3C;
P < 0.05). Thus, in primary cortical neurons, GA-activated M8
effectively prevented loss of synapses and defects in arborization
of neurite processes induced by both Aβ42 fibrils and oligomers.
MMP-9/Extracellular Degradation Is
Predominant for Macrophage Clearance of
Aβ42 Oligomers
To investigate how macrophages, including GA-activated
macrophages, facilitate clearance of Aβ42 oligomers vs. fibrils
and potentially increase synaptic protection, we characterized
M8 phenotypes, with and without GA stimulation, in response
to the same quantities of XL-oAβ42 and pre-formed fAβ42
(100 nM; Figure 4). First, to assess surface recognition and
intracellular uptake of Aβ42 assemblies, M8 were incubated
with XL-oAβ42 or fAβ42 for 30min and labeled for Aβ (6E10),
early endosome antigen 1 (EEA1), and class B scavenger receptor
CD36 or class A type 1 scavenger receptor SCARA1 (encoded
by macrophage scavenger receptor 1 – MSR1 gene). There was
a notable increase in CD36 expression, intracellular o/fAβ42,
and o/fAβ42 colocalized within EEA1 endosomes in GA-M8 vs.
naïve M8 (Figures 4A, B). A quantitative analysis of scavenger
receptors indicated a significant increase in CD36 expression
(Figure 4C; P < 0.01; Supplementary Figure 4A; P < 0.05)
in GA-M8 compared to untreated M8, but not in SCARA1
for XL-oAβ42 (Supplementary Figure 4B). Regardless of GA,
exposure to Aβ42 oligomers substantially upregulated surface
expression of CD36 in M8 (Figure 4C; P < 0.001). GA-M8
exhibited significantly more intracellular uptake of both fAβ42
and XL-oAβ42 vs. naïve M8 (Figures 4D,E; P < 0.0001 and P
< 0.001, respectively). Both naïve and GA-M8 were on average
six times less effective in intracellular uptake of oligomeric vs.
fibrillar Aβ42 (Figure 4D vs. Figure 4E). Strikingly, as compared
with fibrils, Aβ42 oligomers were approximately 2,500 times
less targeted into early endosomes (Figure 4F vs. Figure 4G), as
measured by 6E10+-Aβ puncta number colocalized in EEA1+
vesicles after 30min phagocytosis assay. Hence, these data
suggest that while intracellular Aβ42 fibrils are predominantly
targeted to the endosomal-lysosomal proteolysis pathway,
intracellular oligomers mostly escape these proteolytic vesicles in
M8. Nonetheless, GA-M8 significantly increased the presence
of both Aβ42 fibrils and oligomers in EEA1
+ endosomes
(Figures 4F,G; P < 0.01–0.0001).
Next, we evaluated the extent to which M8BM degrade Aβ42
oligomers as compared to fibrillar forms in the extracellular
space. To this end, we first assessed the expression of matrix
metallopeptidase 9 (MMP-9)—an Aβ-degrading enzyme—by
analysis of MMP-9+-immunoreactive area in M8 (Figure 4H).
Then, we determined Aβ1−42 concentrations in supernatant of
M8 following incubation with 100nM of either fAβ42 or XL-
oAβ42, using a highly sensitive ELISA assay (Figure 4I). We
previously showed that after exposure to Aβ42 fibrils, GA-M8
exhibited a significant increase in MMP-9 levels (63, 70). Yet,
the response to oligomers has not been reported. Here, we found
that MMP-9 expression in GA-M8 was markedly increased
after incubation with XL-oAβ42 (Figure 4H; P < 0.0001).
Examination of extracellular degradation as a function of Aβ42
conformation indicated significant decreases in concentration of
Aβ42 in the media of GA-M8 vs. naïve M8 after 24 h incubation
with either fAβ42 or XL-oAβ42 (Figure 4I; 36 or 62% reduction,
respectively, P < 0.01). Likewise, the substantial reduction in
fAβ42 and XL-oAβ42 concentrations in the extracellular media
of GA-treated vs. untreated M8 can be seen after 30min of
incubation with these Aβ species (Supplementary Figures 4C,D;
P < 0.001). Notably, at the two incubation time points
(30min and 24 h incubation), Aβ42 oligomers were primarily
degraded in the extracellular rather than the intracellular
space of macrophages and were considerably more accessible
for extracellular degradation than their fibril counterparts
(Figure 4I; 32% vs. 12 and 62% vs. 36% for M8 and GA-
M8, respectively; Supplementary Figures 4C,D; P < 0.001).
Representative microscopic images in Figure 4J panel illustrate
the increase in oAβ42 uptake and CD36 expression by GA-
activated M8, along with a decrease in extracellular or synaptic-
bound oAβ42, which resulted in synaptic and neuritic outgrowth
preservation in primary cortical neurons. Overall, these data
suggest that GA induces CD36/EEA1-mediated macrophage
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FIGURE 4 | Induced oligomeric Aβ42 clearance via GA activation of CD36/EEA1-intra- and MMP-9-extracellular mechanisms in M8, leading to neuronal preservation.
(A–G) GA-activated (24 h) or naïve M8 were exposed to 100 nM Aβ42 assemblies for 30min, and co-labeled for Aβ (6E10, green), type B scavenger receptor
CD36 (magenta), and early endosomal marker (EEA1, red). Cells were counterstained with DAPI (blue). Representative micrographs demonstrate elevated surface
CD36 expression, intracellular Aβ, and Aβ colocalized within EEA1 endosomes in GA-M8 vs. control M8, 30min fAβ42 (A) and XL-oAβ42 (B) uptake assays. (C)
Quantitative immunoreactive analysis of CD36 signals showed a substantial increase in CD36 in GA-M8. Basal levels of CD36 expression without Aβ42 were higher in
(Continued)
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FIGURE 4 | GA-M8 vs. control M8. This increase maintained its significance after exposure to XL-oAβ42. Regardless of GA effects, the presence of oligomeric Aβ42
substantially increased CD36 levels in both control M8 and GA-M8. (D,E) Quantitative analysis of intracellular Aβ in M8 following 30min fAβ42 (D) and XL-oAβ42 (E).
(F,G) Quantitative analysis of fAβ42 (F) and XL-oAβ42 (G) within EEA1-positive vesicles in early endosomes in GA-M8 vs. control M8. Co-labeled 6E10/EEA1-
immunoreactive puncta number per M8 is displayed. (H) Increased MMP-9 signal in GA-M8 after exposure to XL-oAβ42. (I) ELISA quantification of extracellular Aβ42
after 24 h incubation with fAβ42 or XL-oAβ42 compared to 30min basal peptide levels. (J) Representative microphotographs of co-cultured P1 neurons and M8
exposed to XL-oAβ42 for 24 h, stained with CD36, 6E10, Tubb3, and DAPI. P1 cortical neurons co-cultured with GA-M8 vs. control M8 exhibit increased neuritic
outgrowth density with increased CD36-mediated Aβ uptake (arrows) and reduced extracellular Aβ42. Data expressed as mean ± s.e.m., with individual data point; n
= 48 fields analyzed from 3 independent experiments; immunoreactive areas are normalized by cell number; **P < 0.01, ***P < 0.001, ****P < 0.0001, GA-M8 vs.
M8 with fAβ42 or XL-oAβ42, and
###P < 0.001, ####P < 0.0001 for comparisons to M8 without Aβ [(–) Aβ42], by one-way ANOVA with Tukey’s test or two-tailed
student t-test. Scale bar = 20µm.
clearance, and moreover, MMP-9/extracellular degradation of
synaptotoxic Aβ42 oligomers, ultimately protecting synapses,
their dendritic structure, and neural function.
Severe Loss of Excitatory Pre- and
Postsynaptic Terminals in the Entorhinal
Cortex and Hippocampus of ADtg Mice
Given the crucial role of entorhinal cortex layers 2 and
3 in connecting brain cortical regions to the hippocampus,
we sought to analyze pre- and postsynaptic VGluT1 and
PSD95 biomarkers in substructures of the entorhinal cortex
(ENT) and hippocampus (HIPPO) of 10- and 13-month-old
symptomatic ADtg vs. wild type (WT) mice (Figures 5A–E;
Supplementary Figures 5–8). Due to lack of differences between
the lateral (ML-L) and the medial (ML-M) blade molecular
layers in pre- and postsynaptic areas across all experimental
groups (Supplementary Figure 5), both regions were combined
in our analyses (Figures 5D,E). Ten-month-old ADtg mice
already exhibited significant pre- and postsynaptic losses in
the molecular layers (ML) of the dentate gyrus (DG) and
the stratum lacunosum-moleculare (SLM), but not in the
stratum oriens (SO) nor in the stratum radiatum (SR) of
the cornu ammonis 1 (CA1; Supplementary Figure 6). At 13
months, ADtg mice exhibited 50-62% presynaptic VGluT1-
immunoreactive (IR) area loss in all hippocampal regions as
compared to WT mice (Figure 5D; P < 0.05–0.001). Similarly,
analyses of postsynaptic PSD95-IR areas in 13-month-old ADtg
mice vs. WT littermates indicated significant reductions by 28–
42% in all hippocampal regions (Figure 5E; P < 0.05). In ENT
layers 2 and 3, 68 and 53% of presynaptic VGluT1-positive
areas were lost (Figure 5D; P < 0.001), while 38 and 51% of
postsynaptic PSD95 signals were reduced (Figure 5E; P < 0.05
and P < 0.01) in ADtg mice compared to WT mice, respectively.
Overall, our data demonstrate a progressive and considerable
loss of VGLUT/PSD95 synaptic density, while the presynaptic
VGluT1 terminals appear more vulnerable to Aβ accumulation
in the 13-month ADtg animals.
Synaptic Rescue Following Enhanced
Cerebral Recruitment of Macrophages via
Immunomodulation Therapy in ADtg Mice
To better understand the role of peripheral Mo/M8 in
preservation of excitatory synapses within AD-relevant
cortical and hippocampal regions, we analyzed both pre-
and postsynaptic density in substructures of ENT and HIPPO
following weekly s.c. injections of GA immunization or
monthly i.v. injections of CD115+ MoBM into the peripheral
blood (schematic of in vivo experiment in Figure 5C). Rescue
pre- and postsynaptic density was noted in ENT2/3 by GA
immunization or blood enrichment with MoBM in ADtg mice
(Figures 5F,G, P < 0.05–0.001; Supplementary Figure 7, P
< 0.05–0.01). Similarly, GA led to rescue of pre-VGluT1
and post-PSD95 synapses in HIPPO across various ML,
SLM, SR, and SO subregions (Figures 5F,G, P < 0.05–0.01;
Supplementary Figure 8). Notably, throughout the analyzed
brain regions, both immunomodulation approaches rescued
postsynaptic density (i.e., PSD95-IR area) in symptomatic ADtg
mice to levels similar or higher than those observed in WT mice
(Figure 5G; Supplementary Figures 7B, 8B). No cumulative
effect was noted between a group of ADtg mice treated with both
GA and MoBM (combined treatment) and groups of mice treated
with GA or MoBM alone (data not shown). Taken together,
our in vitro and in vivo data suggest that immunomodulation
approaches that deliver macrophages to reduce pathogenic
Aβ42 burden at synaptic clefts substantially preserve pre- and
postsynaptic terminals.
To identify confounders that potentially predict excitatory
synaptic loss and contribute to immunotherapy-based synaptic
preservation, we carried out multiple Pearson’s coefficient
(r) correlation analyses in the 13-month-old mouse cohort
(Supplementary Figure 9). Specifically, we explored possible
relationships between synaptic integrity and parameters of
disease stage (cognitive function in Barnes maze test, astrogliosis,
and amyloidosis) and therapeutic response (cerebral M8
recruitment and phenotype). A strong linear association
was observed between cerebral astrocytosis (GFAP+ reactive
astrocyte area) and impaired cognitive function, as measured by
error count on day 7 (long-term memory retention) of Barnes
maze test (Supplementary Figure 9A; P = 0.0187, Pearson’s
r = 0.60). Similar correlations were found between hippocampal
and cortical astrogliosis and other parameters of cognitive deficit
in the Barnes maze test (not shown), suggesting that astrogliosis
is a strong predictor of cognitive decline. Comparable to these
observations, tight correlations were detected between cortical
astrocytosis and postsynaptic loss (Supplementary Figures 9B–
D; P = 0.028–0.007 and Pearson’s r = −0.55 to −0.61).
These data show an association between astrogliosis and
cognitive outcome.
In relation to Aβ-plaque pathology, both cortical and
hippocampal regions further revealed close inverse associations
with postsynaptic density (Supplementary Figures 9E–H; P =
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FIGURE 5 | Cortical and hippocampal synaptic rescue by CD115+-monocyte blood enrichment and GA immunization in ADtg mice. (A,B) VGluT1/PSD95 synaptic
quantification scheme in entorhinal cortex (ENT) and hippocampus (HIPPO). (A) (Middle) Representative crystal violet stained image of a coronal brain section at
(Continued)
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FIGURE 5 | Bregma −2.65mm. Scale bar = 1mm. (Left) Representative microimage of HIPPO stained with the presynaptic (VGluT1, red) and postsynaptic (PSD95,
green) markers. Note that 3 fields are chosen in each of the lateral and medial blade molecular layers (ML) of dentate gyrus (DG), as well as in the stratum
lacunosum-moleculare (SLM), stratum radiatum (SR), and stratum oriens (SO) of CA1. (Right) Representative microphotograph of ENT immunolabled with the same
pre- and postsynaptic markers. Note that ENT adjacent to piriform cortex (PIR) and 2 same fields are precisely selected from layers 2 and 3. Scale bar = 100µm. (B)
Representative microphotographs from the lateral blade ML immunostained with the same synaptic markers. Each high-magnification maximum intensity projection
(MIP) image contains 15 Z-stack optical scanning (left). Scale bar = 10µm. (Middle) Magnification for visualizing the proximity of pre- and postsynaptic signals. Scale
bar = 2µm. (Right) Schematic representation of pre- and post-terminal synapse. (C) Schematic of the in vivo experiments, where 10-month-old ADtg mice (all males)
were injected with weekly s.c. GA immunization or monthly i.v. CD115+-MoBM injections for a duration of 2 months. Control groups were either naïve WT mice or
monthly i.v. PBS injected ADtg mice. At the completion of the experiment, mice underwent behavioral testing, were euthanized, and brains were collected for
analyses. (D,E) Quantification of presynaptic VGluT1 (D) and postsynaptic PSD95 (E) areas in ENT2/3 and hippocampal substructures of 13-month-old ADtg mice vs.
age-matched WT littermates. (F,G) Quantification of VGluT1 (F) and PSD95 (G) immunoreactive areas in the entorhinal cortex, hippocampus, and whole brain of WT,
GA-immunized, MoBM-injected, and PBS-control mice. Data expressed as mean ± s.e.m.; n = 6 mice per group; *P < 0.05, **P < 0.01, ***P < 0.001, and
#P < 0.001, ##P < 0.0001, compared to ADtg control; @P < 0.05 compared to MoBM, ∧P < 0.05 compared to GA, one-way ANOVA with Tukey’s test.
0.011–0.002 and Pearson’s r = −0.57 to −0.70). Similar
correlations were also observed for presynaptic areas (not
shown). These data suggest that cerebral Aβ-plaque burden are
important indicators of synaptic loss in this murine model. We
then established the relationship between excitatory synaptic
integrity and cognition, showing significant associations between
hippocampal and cortical synaptic density and cognitive function
(Supplementary Figures 9I,J; P = 0.015–0.009 and Pearson’s
r = −0.45 to −0.53). The latter cognitive performance was
determined by escape latency times in the learning and memory
reversal phase on day 9 of the Barnes maze test. These data
suggest that synaptic integrity is tightly associated with cognitive
function, and that both astrogliosis and amyloidosis adversely
affect it.
We previously showed that effective immunomodulation
approaches in ADtg mice, such as GA immunization or
blood enrichment with MoBM, reduced Aβ-plaque pathology
and preserved cognition (50, 52, 63, 70). These therapeutic
effects were achieved via cerebral recruitment of Iba-
1+/CD115+/CD45hi Mo/M8 that expressed high levels of
osteopontin (OPN; encoded by the gene secreted phosphoprotein
1 or SPP1) (63, 70). OPN/SPP1 is an immunoregulatory cytokine
shown to both promote synaptogenesis (93–95) and be crucial
for M8-mediated Aβ42 clearance (70). Significant and strong
associations were observed between cerebral and hippocampal
Iba-1+/CD45hi Mo/M8 (Mo/M8 cell count) and cognitive
function, as measured by latency times and error counts on
day 9 of the Barnes maze test (Supplementary Figures 9K,L;
P = 0.0472–0.011 and Pearson’s r = −0.64 – −0.76). We
further found a significant and robust association between
OPN and postsynaptic but not presynaptic density areas
(Supplementary Figures 9M,N; P = 0.0133 and Pearson’s r =
0.69). These analyses suggest that increased Mo/M8-mediated
OPN/SPP1 presence in the brain is linked with synaptic integrity
and cognitive preservation.
DISCUSSION
This study supports the conclusion that activated M8BM can
reduce Aβ42 oligomers and protect synaptic integrity and
neuronal structure. Initially, we determined the impact of
defined and stabilized populations of soluble Aβ42 oligomers on
excitatory synapses, neuritic arborization, and neuronal function
as compared to pure fibrils. We indicated that synaptotoxicity
was not elicited by non-aggregating sAβ42 peptides but was
dependent on their conformation state; cortical neurons were far
more vulnerable to Aβ42 oligomers than to fibrils. Aβ42 oligomers
caused severe synaptic loss, neurite arborization retraction,
and hyperactivity, as well as changes in two critical features
of the extracellular waveform in cortical neurons. We further
found that M8BM effectively protect against synaptic loss and
neurite retraction caused by Aβ42 fibrils yet provide insufficient
protection against oligomers. Importantly, M8 activation with
glatiramer acetate (GA, an FDA-approved drug) fully protected
neurons from detrimental effects triggered by both oligomers
and fibrils. We identified distinct M8-mediated mechanisms for
clearance of oligomers as compared to fibrils leading to synaptic
protection. While eradication of Aβ42 oligomers predominately
involves increased extracellular/MMP-9 degradation, fibrils are
primarily eliminated via CD36/EEA1+-endosomal intracellular
proteolysis. Strikingly, both pathways are boosted in M8
stimulated with GA. Finally, our in vivo studies corroborated
the in vitro findings, demonstrating that loss of cortical and
hippocampal excitatory synapses in transgenic mouse models of
AD is reversed by increased cerebral recruitment of Mo-derived
M8, achieved via GA immunomodulation or peripheral-blood
enrichment of BM-derived monocytes. Overall, these findings
should guide future therapeutic interventions for AD to boost
M8-mediated clearance of synaptotoxic Aβ42 oligomers and
preserve synapses and cognition.
Our data in mouse primary cortical neurons provide evidence
to support the notion that Aβ42 oligomers pose a greater
threat to the neuronal network than do fibrils. These results
align with previous studies reporting that Aβ42 oligomers
impair neuronal plasticity and activation of excitatory mGluR
hippocampal neurons, as well as exhibit direct synaptotoxic
effects leading to cognitive impairments (8, 13, 15, 23–29, 96).
As compared to postsynaptic terminals, presynaptic terminals
displayed greater vulnerability to Aβ42 assemblies in both in
vivo and in vitro models. We found that compared to fibrils,
stabilized Aβ42 oligomers caused greater synaptic loss and
neuritic retraction along with hyperactivity and altered action
potential shape in primary cortical neurons. Due to the massive
reduction in synapses (∼70%) observed in response to Aβ42
oligomers as early as 12 h after incubation, a corresponding
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reduction in neuronal activity was anticipated. To the contrary,
however, we found elevated levels of spontaneous activity
after incubation with oligomers. These observations are in
accordance with previous studies in murine models of AD
that showed increased neuronal excitability near Aβ plaques
or in Aβ-depositing mouse brains, using Ca2+ imaging and
in vivo intracellular recording (97, 98). Combined with the
modified action potential shape we documented, this suggests
that oligomeric Aβ42 directly affects the biophysical (intrinsic)
properties of neurons, possibly via altered ion channel densities,
in addition to its effects on synapses. Because oligomeric Aβ42
species are highly metastable and exist in dynamically changing
mixtures, the conclusions of previous reports on Aβ42 oligomers
may have been confounded by the existence of heterogeneous
Aβ populations. By using defined and stabilized Aβ42 oligomers,
this study establishes the precise neuropathological consequences
caused by oligomers vs. fibrils and supports therapeutic avenues
that clear cerebral Aβ42 oligomers to prevent such neuronal and
synaptic damage.
One powerful method to clear Aβ42 oligomers and protect
synapses was revealed in this study. Cortical neurons that were
severely impaired by Aβ42 oligomers showed partial recovery
of pre- and postsynaptic density and neurite arborization when
co-cultured with M8BM, and full recovery with GA-M8. While
naïve M8 were able to effectively protect against synaptic
and neurite length loss caused by the fibrils, they exhibited
poor capacity to prevent oligomeric-induced synaptotoxicity.
Yet, GA-M8 successfully eliminated both fibrils and oligomers,
essentially protecting neuronal network integrity despite these
adverse conditions. Postsynaptic terminals, which were less
vulnerable to Aβ42 species, were fully rescued by the presence
of GA-M8. However, it would be interesting to look at
the alteration of inhibitory gephyrin immunosignal expression
following the administration of GA or GA-M8. We discovered
that the EEA1+-early endosomal/lysosomal pathway was far
more involved in the M8-mediated engulfment of fibrils
than of oligomers. In contrast, reduction of Aβ42 in the
extracellular space of M8 was substantially more efficient
for oligomers than for fibrils, potentially through enhanced
release and activity of proteolytic enzymes (i.e., MMP-9).
These in vitro data corroborate our in vivo studies in ADtg
mice that demonstrated enhanced MMP-9 expression by
infiltrating macrophages surrounding cerebral Aβ plaques in
GA-immunized animals (63, 70). Notably, GA enhanced both
internalization and extracellular pathways in M8 to break
down synaptotoxic Aβ42 forms. Recent studies indicated that
depleting microglia with colony-stimulating factor 1 receptor
(CSF1R) signaling inhibitors could impair formation of the
plaques in an AD model (99, 100). Microglial depletion was
further found not only to lead to a complete rescue of deficits in
proliferation, differentiation and survival of adult hippocampal
neural progenitor cells (101), but also significantly reduce
ApoE, which is a major constituent of amyloid plaques and
promotes their aggregation and deposition (102). It would be
interesting to look at changes of synapses, Aβ deposition and
cognition when microglial depletion plus GA immunotherapy
is applied to this ADtg model. Additional studies are needed to
further establish direct structure-function connection between
these and other Aβ42 forms (e.g., dimers, trimers, etc.),
synaptotoxicity, and macrophage-mediated synaptic protection.
A limitation of this study is that it does not allow for
conclusions regarding potential rescue of neuronal function
by macrophages due to lack of electrophysiological studies
in macrophages and neurons co-cultures. Yet, since this
study clearly demonstrates neuroprotection by morphological
(neurite length) and synaptic biomarker measurements, future
studies should evaluate whether these are accompanied with
functional protection.
In this study, we demonstrated that progressive cortical
and hippocampal pre- and postsynaptic loss tightly correlated
with increased cerebral Aβ burden in the double-transgenic
APPSWE/PS11E9 murine model. The direct association between
pre- and postsynaptic biomarkers and cognitive scores further
emphasizes a potential link between Aβ42, synaptotoxicity, and
cognitive decline. Moreover, the unexpected strong association
between synaptic density and GFAP+ astrogliosis suggested that
beyond direct Aβ toxicity, chronically reactive astrocytes not only
fail to protect synapses, but also detrimentally impair them and
lead to cognitive decline. Future investigations are warranted to
better understand the impact of astrocytes and their phenotype
on synaptic and cognitive decline in AD.
Here, we showed that both immunotherapies—GA
immunization or blood-enrichment with CD115+ monocytes—
restored presynaptic and fully rescued postsynaptic density
in ADtg mice exhibiting significant synaptic loss. In our
previous studies, these immunomodulation approaches have
led to increased cerebral infiltration of monocyte-derived
macrophages directly involved in Aβ clearance, leading to
improved hippocampal-based memory and learning (52, 63).
In this study, cognitive function, which directly correlated
with synaptic integrity, also strongly associated with cerebral
recruitment of (GFP+) Iba1+/CD45high monocytes and
macrophages. These data suggest that M8 activity in the brain
associated with decreased synaptotoxic Aβ levels can enhance
synaptic protection and regeneration. One interesting question
would be what happens if microglia as residential macrophages
are treated with GA. Immunophenotypes of microglia expressed
differently in dementia with AD pathology. For example,
Iba1 was negatively associated with AD while levels of CD68,
MSR-A, and CD64 expression were positively related to the
presence of dementia (103). In a previous paper we determined
a significant reduction of GFAP expression in the cortex of AD
mice following GA or/and GA-M8 immunotherapy (63), and
found GFAP expression in this model was negatively associated
with pre-synapse VGluT1. We now further demonstrated that
the relationship of GFAP levels vs. post-synapse PSD95 in the
cortex of AD mice exhibits the same behavior pattern as that of
GFAP vs. VGluT1.
Cerebral clearance of Aβ by innate immune cells has
been shown to take place via multiple mechanisms, including
phagocytosis and enzymatic degradation (48, 49, 51, 54, 56,
57, 61, 104–106). Increasing evidence over the past decade
has established the notion that peripheral M8 contribute
to the phagocytosis of cerebral Aβ plaque, an idea that is
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further supported by reports of defective Aβ phagocytosis
by M8 isolated from AD patients (52, 53, 58, 60, 63, 104,
107). Several studies corroborating this idea have shown
the involvement of scavenger receptors such as CD36 and
SCARA-1 in facilitating fibrillar Aβ engulfment by innate
immune cells. Rare variants in the TREM2 gene were also
associated with diminished M8 phagocytosis and increased
risk for AD (108–110). Indeed, parallel to the aforementioned
investigations, this study’s findings indicated elevated levels
of surface scavenger receptors (e.g., CD36) in response to
not only fibrillar but also oligomeric Aβ42, with increased
uptake by GA-M8. Importantly, the role of M8 and,
moreover, GA-activated M8 in the clearance of non-fibrillar
oligomeric Aβ forms has not been previously studied (111,
112). Enhanced colocalization of oligomers and fibrils in
EEA1+-vesicles in GA-M8 imply that these Aβ assemblies
are redirected to lysosomal degradation rather than for
perinuclear or endoplasmic reticulum pathologic accumulation
(113). Therefore, this FDA-approved drug emerges again as
a promising modality to safely stimulate phagocytic M8 and
improve ability to resist synaptotoxic Aβ forms associated
with AD.
In the absence of Aβ, cortical neurons supplemented with
GA-M8 exhibited elevated levels of synaptic density and
neuritic length that were higher than that of the baseline
levels detected in cortical neurons alone. These results suggest
that increased synaptic density in the presence of GA-M8
is a result of both Aβ42 clearance and upregulation of
neurotrophic factors stimulating synaptogenesis, such as insulin-
like growth factor 1 (IGF-1), transforming growth factor beta
1 (TGFβ1), and/or OPN/SPP1 (50, 66, 70). In our previous
study, we observed that OPN/SPP1 was markedly elevated
in M8 following GA treatment in vitro and in vivo (70).
Here, a strong correlation (Pearson’s r = 0.7) was found
between cerebral OPN/SPP1 levels and postsynaptic density,
which can explain increased synaptogenesis in the presence
of M8BM overexpressing OPN in the brains of immunized
ADtg mice (70). In support of these findings, we reported
that harnessing monocyte-derived macrophages by GA- or
MOG-45D-immunization in ADtg mice enhanced cerebral
expression of neurotrophic factors such as IGF-1, TGFβ1, and
nuclear transcription factor early growth response 1 (Egr-
1) (50, 58, 66), concomitant with recovered hippocampal
neurogenesis. Hence, this immunomodulation approach holds
great promise to positively affect neural regeneration as well
as synaptic and cognitive preservation through combined M8
activity of eradicating pathogenic Aβ42 forms and increasing
neurotrophic support.
In conclusion, therapeutic approaches designed to prevent
synaptotoxicity or even rescue synapses are becoming more
prominent. Our extended data from both in vitro and in vivo
studies may signify that GA-stimulated macrophages confer a
potential synaptoprotective phenotype, at least in part through
augmented capacity to eliminate highly toxic Aβ42 oligomers and
induce synaptic preservation and regeneration. Hence, this study
encourages the development of a macrophage-based approach as
therapeutic intervention for AD.
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